The scale of the problem is staggering. Cancer is responsible for roughly one in six deaths worldwide, according to 2022 estimates, and about one-third of all cancer deaths are considered attributable to cancer-associated cachexia. More than half of all patients with cancer have some degree of cachexia by the time they die. Yet despite its prevalence, the syndrome remains poorly understood by the public and, as the new review makes clear, inconsistently defined even within the research community. Cachexia is not simple starvation. It is a complex, multifactorial metabolic disorder characterized by anorexia, unintentional body weight loss and loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support. Systemic inflammation, reflected in elevated C-reactive protein, low serum albumin and an elevated neutrophil-to-lymphocyte ratio, is another biochemical hallmark that distinguishes it from malnutrition, which can be readily corrected with adequate feeding.

The review team searched Embase, MEDLINE and the Cochrane Library for publications from 2018 to 2023, ultimately identifying 40 publications representing the 37 unique studies. The overwhelming majority, 35 of 40 publications or 94.6 percent, were observational studies, with the remaining two being post hoc analyses of randomized trials. Sample sizes ranged dramatically, from as few as 38 patients to approximately 17,000, and mean or median patient ages spanned 45 to 79.6 years. This breadth gives the analysis considerable weight, capturing as it does predominantly real-world populations rather than the highly selected cohorts typical of clinical trials.

One of the review’s most striking methodological findings is the sheer inconsistency in how cachexia is diagnosed. Across the 40 publications, the researchers counted 11 different definitions of cachexia or body weight loss. The most commonly used was the Fearon et al. 2011 International Consensus criteria, employed in 18 publications, or 45 percent of the sample. That consensus definition requires more than 5 percent weight loss in the previous six months, or more than 2 percent weight loss in patients whose body mass index falls below a threshold or whose condition includes sarcopenia. The remaining studies used a patchwork of alternative criteria, and prevalence estimates for the condition swing wildly depending on which is applied. A recent meta-analysis found a prevalence of 33 percent using the Fearon criteria but a range of 13.9 to 56.5 percent with other definitions. The authors argue this fragmentation undermines both clinical care and research, and they issue a clear call for standardization.

The functional consequences documented in the review are sobering. Nineteen distinct outcome types were reported across the studies. Physical function measures appeared in 31 studies, health-related quality of life in 24, performance status in 16, pain and fatigue in 15 each, depression or anxiety in nine, and activities of daily living in six. When the researchers examined how consistently cachexia was linked to worse outcomes, the associations were remarkably robust. Among studies assessing physical function, 80.6 percent, or 25 of 31, identified a statistically significant association with cachexia or weight loss in at least one outcome. For health-related quality of life the figure rose to 91.7 percent, and for performance status, the clinician-rated scale that often determines eligibility for chemotherapy, it reached 87.5 percent. Pain was significantly worse in 78.6 percent of relevant studies and fatigue in 73.3 percent. Most striking of all, every single study, six out of six, that assessed activities of daily living found patients with cachexia significantly more impaired. Only depression and anxiety showed a weaker, though still majority, association, at 55.6 percent.

These numbers translate into a lived reality that oncologists see daily but which has rarely been quantified so systematically. A patient with cachexia may find that a course of chemotherapy they can barely tolerate is also less effective, because the syndrome is associated with treatment failure and heightened toxicity. The loss of muscle mass compromises the body’s ability to metabolize drugs and recover from treatment-related damage. Fatigue and pain compound one another, and the growing inability to perform basic tasks such as bathing, cooking or walking to the shops deepens the psychological toll. In the aggregate, cachexia shortens survival independently of tumour burden, making it one of the most consequential yet under-treated syndromes in oncology.

The review’s authors emphasize that their findings carry direct implications for drug development. No effective therapy for cancer cachexia is currently available, despite years of research into molecular mechanisms ranging from inflammatory cytokine signalling to myostatin inhibition and appetite regulation. Several investigational clinical trials are now underway, and these studies frequently use measures of physical function as trial endpoints. A 2023 systematic review by McDonald and colleagues examined this endpoint landscape, and the new analysis extends that work by detailing precisely how cachexia relates to function in everyday clinical settings. Choosing endpoints that accurately reflect what matters to patients, the authors argue, is essential if emerging therapies are to demonstrate meaningful clinical benefit rather than merely slowing weight loss.

At the same time, the heterogeneity documented in the review poses a genuine obstacle. Beyond the 11 diagnostic definitions, the studies employed a wide array of physical function metrics and patient-reported outcome instruments, from handgrip dynamometry and gait speed to multi-domain questionnaires. Eleven outcome types were evaluated exclusively in univariate analyses, while eight were assessed in multivariate models that could adjust for confounders such as tumour stage and treatment intensity. The authors caution that this methodological diversity complicates cross-study comparison and weakens the evidence base, reinforcing their appeal for standardized diagnostic criteria and a core set of outcome measures that future trials and observational studies should adopt.

For patients and families, the message is that weight loss in cancer should never be dismissed as an inevitable side effect to be managed with extra nutrition alone. Because standard supplementation cannot reverse the cachectic process, clinicians increasingly recognize the syndrome as a distinct medical entity requiring targeted intervention, ideally before severe muscle loss has occurred. The review’s demonstration that activities of daily living are universally impaired in cachectic patients underscores how early and how completely the syndrome invades independence, and it suggests that preserving function, not merely weight, should be a central goal of care.

As candidate therapies move through the pipeline, this synthesis of more than 50,000 patients provides both a benchmark and a roadmap. It confirms that cancer cachexia degrades physical function, quality of life, performance status, pain, fatigue and mood in predominantly real-world populations, and it identifies the measurement gaps that must be closed before the next generation of trials can convincingly demonstrate benefit. For a condition implicated in a third of cancer deaths and lacking any approved treatment, that clarity is long overdue.